Skip to content

Deep Neck Flexor Exercises Versus Myofascial Release of Suboccipital Muscles in Chronic Tension-type Headache

Not yet recruitingNot applicableNCT05383365
View the official record on ClinicalTrials.gov

Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.

This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.

Brief summary (from the registry)

According to the study of the burden of diseases in 2018, tension-type headache(TTH) is the most common type of primary headache and ranks third in terms of prevalence among 328 diseases and injuries in 195 countries from 1990 to 2016. Suffering from this disorder (especially chronic type) reduces the quality of life of patients. The main objective of this study is to compare the effects of myofascial release of suboccipital muscles as a bottom-up intervention and Deep Neck Flexor(DNF) exercises with Pressure Biofeedback Unit(PBU) as a top-down intervention on headache parameters, the intensity of Forward Head Posture(FHP), disability, quality of life, and suboccipital Pressure Pain Threshold(PPT) in patients with chronic tension-type headache with forward head posture.

Study details

Official title
The Effectiveness of Deep Neck Flexor Exercises in Comparison With Myofascial Release of Suboccipital Muscle on Pain and Forward Head Posture in People With Chronic Tension-type Headache and Forward Head Posture
Conditions
  • Chronic Tension-Type Headache
Interventions
  • Other: Suboccipital Myofascial Release(MFR) with sham Deep Neck Flexor(DNF)exercise
  • Other: Deep Neck Flexor(DNF)exercise with sham Suboccipital Myofascial Release(MFR)
Sponsor
Iran University of Medical Sciences
Start date
2024-11-01
Primary completion
2025-12-01
Sex
All
Age range
from 18 Years to 55 Years
Results posted
No results posted in this snapshot
Total sites listed
0

Eligibility criteria

Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. Age between 18 and 55 years; 2. based on ICHD-3, Headache that occurs 15 days per month and lasts on average for \>3 months (180 days per year), lasting hours to days, or unremitting, and has at least two of the following four characteristics recognized as CTTH: bilateral location, pressing or tightening (non-pulsating) quality, mild or moderate intensity, not aggravated by routine physical activity such as walking or climbing stairs and both of the following: no more than one of photophobia, phonophobia or mild nausea, neither moderate or severe nausea nor vomiting; 3. Dosage and type of prophylactic medication have not changed in the months before the beginning of the trial; 4. The participant does not intend to change the dosage and type of prophylactic medication during the study; 5. CVA less than 49 degrees, 6. Participants have the ability to understand and read Persian to complete the questionnaire. Exclusion Criteria: 1. Participants with infrequent ETTH, or other primary or secondary types of headache; 2. Pain aggravated by movement of the head; 3. Severe pain or significant decrease in ROM of the cervical spine; 4. Previous trauma to the cervical spine; 5. History of injection, surgery, severe disc protrusion, or neck or shoulder fracture that affects treatment; 6. Metabolic or Neurological disorders such as Bow hunter's syndrome or epilepsy; 7. Taking more than 200 pieces of morphine or other strong analgesics per month; 8. Physiotherapy treatment for headache within 6 months before starting treatment; 9. Joint stiffness, atherosclerosis, or advanced osteoarthritis; 10. Manual contraindication includes: (a)The participant has substance or alcohol abuse; (b)For whatever reason, the participant does not want to be touched by the therapist; (c)Symptoms are severe and irritating; (d)Underlying diseases (such as rheumatoid arthritis) or metabolic disorders (such as osteoporosis or soft tissue laxity of the treatment area); 11. Pregnancy; 12. Spielberger State-Trait Anxiety Inventory (STAI) scores more than 85; 13. Absence of two consecutive sessions and more than treatment sessions.

Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05383365